Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Innovate, Amarex Sign Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Innovate, Amarex Sign Agreement

To provide data management and biostatistics for its planned Phase 3 celiac disease trial

By: Betsy Louda

, Contract Pharma

Innovate Biopharmaceuticals has signed an agreement with Amarex Clinical Research to provide data management and biostatistics for its planned Phase 3 celiac disease trial. Under the agreement, Amarex will provide Innovate with electronic data capture solutions and associated services for data management and biostatistics.

June Almenoff, M.D., Ph.D., F.A.C.P, chief medical officer and chief operating officer of Innovate said, “With their strong expertise in biostatistics and data management, I am pleased to be working with Amarex to support our Phase 3 trial. Our clinical team has been impressed with Amarex’s capabilities, and we look forward to a productive working relationship.”

Kazem Kazempour, Ph.D., Amarex’s president and chief executive officer, said, “We are excited to support Innovate in the development of its novel therapeutic, which has the potential to help so many patients suffering from celiac disease. We look forward to working closely with Innovate’s experienced team to advance the clinical development of larazotide for this underserved population.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics